Spurred by uptake of Biogen Idec and Elan’s Tysabri (natalizumab) and continued revenue growth for the three beta-interferon brands and Teva’s Copaxone (glatiramer acetate), the seven major multiple sclerosis market value increased 15.1% from 2006 to $5.3 billion in 2007.
Scope
This report gives a strategic analysis of the likely impact that recent events will have on the future multiple sclerosis market
Includes multiple sclerosis-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017
Provides a global market snapshot by including multiple sclerosis-specific sales analysis for leading brands outside the seven major markets
Key conclusions are supported by key opinion leader comment
Report Highlights
Despite the recent confirmation of two new cases of progressive multifocal leukoencephalopathy (PML), with a much stronger 2007-08 enrollment rate than previously anticipated and a greater level of confidence among opinion leaders, Datamonitor has upgraded its Tysabri’s forecast. Datamonitor remains highly positive on Novartis’s FTY720 (fingolimod). FTY720 is expected to achieve the greatest sales of all current late-stage pipeline products. However, sales growth will be restricted from 2012 by the later launch of additional oral pipeline disease-modifiers, which will represent tough direct competition. Genzyme and Bayer Schering’s alemtuzumab (Campath) has been added to this latest multiple sclerosis forecast. Potentially positioned in both the earliest stages of the disease and for rapidly progressing patients refractory on other therapies, a poor perceived safety profile and an assumed low price-point, will limit returns from this market.
Reasons to Purchase
Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2008 to 2017
Quantify the current size of the seven major markets and the trends in the rest of the world
Assess the impact of events, such as patent expiries and new product launches, on the multiple sclerosis-specific sales of key brand name products
